Menu
← Oncology Approval Tracker
FDA DECISION ·
Darzalex Faspro + pomalidomide + dexamethasone
daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with multiple myeloma after at least one line that included lenalidomide and a proteasome inhibitor.
LAMPGEN ANALYSIS
Why it matters
The action adds a subcutaneous daratumumab-based triplet after defined prior drug exposure.
What research teams should watch
Verify the two prior drug exposures and distinguish subcutaneous dosing from the intravenous formulation.
PRIMARY RECORDS